Today: 30 June 2026

Linde plc (LIN) Stock Hits a New 52‑Week Low – Is the Industrial Gas Giant Now Undervalued?

Linde plc (LIN) Stock Hits a New 52‑Week Low – Is the Industrial Gas Giant Now Undervalued?

As of December 8, 2025, shares of Linde plc are trading near fresh 52‑week lows even as the company delivers record earnings, robust cash flows, and growing exposure to energy‑transition megatrends. Midday on Monday, Linde’s own investor page showed the stock at about $391.81, down nearly 2% on the day. linde.com MarketBeat reports that earlier in the session, LIN touched a new 52‑week low around $395.80, well below its 50‑day moving average near $434 and 200‑day around $458. At these levels, Linde trades on roughly 26× earnings with a market capitalization of about $182 billion. MarketBeat
8 December 2025
·
Bloom Energy (BE) Stock on December 8, 2025: AI Data Center Powerhouse or Overheated Trade?

Bloom Energy (BE) Stock on December 8, 2025: AI Data Center Powerhouse or Overheated Trade?

Bloom Energy Corporation has turned into one of 2025’s loudest stock stories. The fuel‑cell maker riding the AI data‑center boom has delivered a life‑changing move for early believers, with the share price up around 1,100% over the past 12 months and several hundred percent year‑to‑date. Benzinga+1 As of U.S. trading on Monday, December 8, 2025, Bloom Energy stock is changing hands near $111 per share, down roughly 7% on the session after another whipsaw day that saw the price swing between about $108 and $121 on heavy volume. TechStock² That intraday volatility caps a wild stretch that included a 17.3% drop in November followed by a sharp early‑December rebound. Yahoo Finance+1
8 December 2025
··
Nebius Group N.V. (NBIS) Stock on December 8, 2025: Latest News, Price Targets and AI Cloud Growth Forecasts

Nebius Group N.V. (NBIS) Stock on December 8, 2025: Latest News, Price Targets and AI Cloud Growth Forecasts

Nebius Group N.V. – the Amsterdam‑based AI infrastructure company spun out of Yandex – remains one of the most closely watched AI cloud stocks going into 2026. On December 8, 2025, the story is being driven by fresh institutional buying, new analyst coverage, and ongoing debate about whether its multi‑billion‑dollar AI contracts justify today’s rich valuation. This article is for information and news purposes only and does not constitute financial advice.
8 December 2025
··
Netflix’s Warner Bros Takeover: How the $82.7 Billion Deal Could Rewrite the Film Market and Movie Distribution

Netflix’s Warner Bros Takeover: How the $82.7 Billion Deal Could Rewrite the Film Market and Movie Distribution

Netflix’s agreement to acquire Warner Bros’ studio and streaming business in a deal valued at about $82.7 billion is the kind of plot twist that rewrites a franchise — in this case, Hollywood itself.Wikipedia+1 If regulators approve it and Netflix fends off a fresh hostile bid from Paramount Skydance, the world’s biggest streamer will control one of the last great legacy studios, HBO, DC, and a century of film history.The Guardian+1 The transaction, announced on December 5, 2025, would see Warner Bros. Discovery spin off its cable networks into a separate company, Discovery Global, while Netflix purchases the streaming and studios division — including Warner Bros. Pictures, HBO, DC Entertainment, TNT Sports UK & Ireland and the games division.Wikipedia+1 The deal values WBD at around $72 billion in equity and $82.7 billion including debt, making it the biggest Hollywood studio sale in history.The Guardian+1
8 December 2025
··
Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

On December 8, 2025, Fluence Energy, Inc. is giving investors a live lesson in volatility. After a huge rally over the past two weeks, the grid‑scale battery and software specialist is trading around $22–23 per share, down roughly 7–8% intraday as fresh analyst downgrades collide with strong growth guidance and a new UK battery storage milestone. The stock is still up more than 30% year‑to‑date and sits close to its one‑year high in the mid‑$20s, after climbing from a 12‑month low near $3.50. Finviz+1
8 December 2025
··
IREN Limited (NASDAQ: IREN) Stock Update: Microsoft $9.7B AI Deal, Capital Raise and Wall Street Forecasts – December 8, 2025

IREN Limited (NASDAQ: IREN) Stock Update: Microsoft $9.7B AI Deal, Capital Raise and Wall Street Forecasts – December 8, 2025

Published: December 8, 2025 IREN Limited has quickly become one of 2025’s most volatile – and most closely watched – AI infrastructure and Bitcoin‑mining names. After a year in which the stock surged several hundred percent, investors are now digesting a massive Microsoft cloud contract, a multi‑billion‑dollar capital raise, and increasingly divided analyst opinions.
8 December 2025
···
SMX Stock Plunges After 500% Weekly Surge: What Security Matters’ December 8 Sell-Off, New Partnerships and 2025 Forecasts Really Mean

SMX Stock Plunges After 500% Weekly Surge: What Security Matters’ December 8 Sell-Off, New Partnerships and 2025 Forecasts Really Mean

SMX Public Limited Company has become one of the most volatile names on the U.S. market in early December 2025. After a breathtaking multi-day rally, the stock is selling off sharply on 8 December even as the company pushes out a wave of partnership press releases across gold, plastics and textiles. This article pulls together all the key SMX stock news, forecasts and analyses available on 8 December 2025, and explains what they may mean for investors following this extremely speculative name.
8 December 2025
··
Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products and Chemicals, Inc. just had a rough session.On December 8, 2025, the stock dropped roughly 9–10%, hit a new 52‑week low around $235–236, and briefly became the worst performer in the S&P 500 after the company announced advanced partnership talks with Yara International on major low‑emission ammonia projects in the U.S. and Saudi Arabia. MarketScreener+1 At the close, APD was around $236 per share, down from a prior close near $260.69, and about 25% below its level a year ago. Investing.com
8 December 2025
··
Caterpillar Stock (NYSE: CAT): Price, Bobcat Lawsuits, Autonomous Truck Deal and 2025–2026 Forecast – December 8, 2025

Caterpillar Stock (NYSE: CAT): Price, Bobcat Lawsuits, Autonomous Truck Deal and 2025–2026 Forecast – December 8, 2025

All figures and opinions below are as of the close on December 8, 2025 and are for information only, not personal investment advice. As of Monday, December 8, 2025, Caterpillar Inc. is changing hands at roughly $595–600 per share, down about 1% on the day but still hovering close to recent all‑time highs. Aggregated quote services show CAT around $595.5–599.5 intraday, depending on the feed. CoinCodex+2MarketBeat+2
8 December 2025
···
Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow. Investing.com+1 This article rounds up the key news and analysis on Legend Biotech stock from December 8, 2025 and the days immediately preceding it, and looks at what Wall Street expects next for LEGN.
8 December 2025
··
CrowdStrike (CRWD) Stock News Today: Q3 2026 Earnings Beat, AWS Awards and Wall Street Forecasts Into 2026

CrowdStrike (CRWD) Stock News Today: Q3 2026 Earnings Beat, AWS Awards and Wall Street Forecasts Into 2026

December 8, 2025 — Midday market update CrowdStrike Holdings, Inc. is back in the spotlight today as one of the most-searched stocks on Zacks and a top “cybersecurity stock to watch” on MarketBeat, following a strong fiscal Q3 2026 earnings report, fresh AI-driven product launches, and new accolades from Amazon Web Services. Finviz
8 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2 The rally caps a stunning year in which Arrowhead stock has delivered a year‑to‑date return of roughly 270% and a one‑year gain in the 160–200% range, depending on the data provider, vastly outpacing the broader market. Yahoo Finance+2Market Chameleon+2
8 December 2025
·
MercadoLibre (MELI) Stock Today: December 8, 2025 Update on Price, Q3 Results, Bond Deal and Analyst Forecasts

MercadoLibre (MELI) Stock Today: December 8, 2025 Update on Price, Q3 Results, Bond Deal and Analyst Forecasts

As of Monday, December 8, 2025, MercadoLibre, Inc. remains one of the most closely watched growth stocks in emerging markets. The Latin American e‑commerce and fintech leader is trading a little above $2,080 per share, giving it a market capitalization of roughly $105–108 billion, with a 52‑week range of $1,646 to $2,645 and a trailing P/E around 50–51. StockAnalysis+1 Yet despite strong fundamentals, the stock has fallen about 15–16% over the last six months, underperforming its e‑commerce peers as investors fret over margin pressure, intense competition and macro volatility in Latin America. Finviz
8 December 2025
··
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase degrader bexobrutideg in blood cancers at the American Society of Hematology Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3 The rally comes barely two months after Nurix posted a weak third quarter and executed a large equity raise, underscoring how heavily sentiment in this name is tied to the clinical trajectory of its degrader pipeline. ChartMill+2StockAnalysis+2
8 December 2025
··
Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana Co. is back in the spotlight. On Monday, December 8, 2025, the online used-car retailer’s shares surged again after S&P Dow Jones Indices confirmed that Carvana will join the benchmark S&P 500 index on December 22, 2025. The stock traded around $454 in late session, up roughly 14% on the day and near record highs, capping a year in which the stock has gained well over 100% and staged one of the most dramatic recoveries in recent market history. Reuters According to Reuters, Carvana’s market value has swelled to roughly $87 billion, now exceeding both Ford and General Motors, and the shares trade at about 57 times forward earnings — a valuation more typical of high‑growth software than a used-car dealer. Reuters
8 December 2025
··
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high above $100, on volume far above normal. MarketBeat The catalyst: very strong Phase 1b data for KT‑621, a once‑daily oral STAT6 degrader for atopic dermatitis and broader Type 2 inflammatory diseases. GlobeNewswire
8 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 Wave Life Sciences Ltd. staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007. Shares surged from a close of $7.49 on Friday, December 5 to intraday levels around $17–18, a gain in the range of 120%–140% and a new multi‑year high. Yahoo Finance+2Investing.com+2
8 December 2025
·
1 … 1,536 1,537 1,538 1,539 1,540 … 2,124

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop